This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Can LabCorp (LH) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
LabCorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
LabCorp (LH) to Offer New Test Report for Venom Allergy Testing
by Zacks Equity Research
LabCorp's (LH) newly-launched interpretative venom allergy report will inform enhanced treatment decisions in case of venomous insect stings.
LabCorp (LH) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
LabCorp's (LH) Diagnostics base business organic volume is anticipated to have continued its rally in Q2, led by consistent growth in esoteric and routine procedures.
LabCorp (LH) Debuts NfL Test for Neuronal Damage Diagnosis
by Zacks Equity Research
LabCorp's (LH) widely accessible NfL blood test presents direct evidence of neuronal injury resulting from brain injury or diseases like Alzheimer's, among others.
LabCorp's (LH) Base Testing Volume Grows, Costs Rise
by Zacks Equity Research
LabCorp's (LH) slew of product launches and collaborations to pursue short- and long-term high-growth opportunities instill optimism.
LabCorp (LH) to Offer Monkeypox Test, Double CDC's Capacity
by Zacks Equity Research
Labcorp (LH) is set to become the first national laboratory to offer this PCR test, verified for the CDC.
LabCorp (LH) to Strengthen Laboratory Footprint in Japan
by Zacks Equity Research
LabCorp's (LH) Drug Development arm, in collaboration with BML, will open a 4,000-square meters lab facility in Kawagoe for global clinical trials.
LabCorp (LH) Partners HealthVerity to Grow in Drug Development
by Zacks Equity Research
According to LabCorp (LH), this partnership is expected to broaden its comprehensive, end-to-end drug development and clinical trial programs.
Here's Why Investors Should Retain LabCorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about LabCorp's (LH) robust Drug Development business performance and several pandemic-related developments.
LabCorp (LH) Gets FDA Nod for VirSeq SARS-CoV-2 NGS Test
by Zacks Equity Research
LabCorp's (LH) VirSeq SARS-CoV-2 NGS Test can detect specific SARS-CoV-2 strains to help health care providers make appropriate patient treatment decisions.
Strength Seen in LabCorp (LH): Can Its 3.7% Jump Turn into More Strength?
by Zacks Equity Research
LabCorp (LH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
LabCorp (LH) Rides on Innovations Amid Cost Constraints
by Zacks Equity Research
LabCorp's (LH) slew of product launches and collaborations to pursue short- and long-term high-growth opportunities instill optimism.
LabCorp (LH) to Enhance Access to OmniSeq INSIGHT via New Program
by Zacks Equity Research
LabCorp's (LH) new sponsored lung cancer program will expand access to comprehensive genomic testing for NSCLC patients to guide informed treatment decisions.
LabCorp (LH) Introduces Latest Assay for Skin Cancer Patients
by Zacks Equity Research
LabCorp's (LH) new assay is claimed to have shown a demonstrable clinical advantage in patients suffering from melanoma.
LabCorp (LH) Debuts At-home Collection Kit for Diabetes Testing
by Zacks Equity Research
LabCorp's (LH) at-home collection kit makes it effortless for consumers to understand their diabetes risk and health status using an innovative and approved collection device.
Here's Why You Should Retain LabCorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about LabCorp's (LH) better-than-expected earnings and robust segmental performance.
LabCorp (LH) Q1 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
LabCorp (LH) reports better-than-expected earnings for the first quarter, with robust sales within the Drug Development arm driving the top line.
LabCorp (LH) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
LabCorp (LH) delivered earnings and revenue surprises of 3.91% and 3.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stocks' Earnings on Apr 28: TMO, BIO & More
by Urmimala Biswas
Medical Products companies' results are likely to reflect a rebound in the base business. Let's see how TMO, BIO, LH and RMD fare this time.
LabCorp (LH) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Robust base business growth and notable launches are likely to have contributed to LabCorp's (LH) Q1 performance.
LabCorp (LH) Stock Moves -0.57%: What You Should Know
by Zacks Equity Research
LabCorp (LH) closed the most recent trading day at $276.30, moving -0.57% from the previous trading session.
Analysts Estimate LabCorp (LH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
LabCorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LabCorp (LH) Gains But Lags Market: What You Should Know
by Zacks Equity Research
LabCorp (LH) closed at $271.14 in the latest trading session, marking a +1.5% move from the prior day.
LabCorp (LH) Gains As Market Dips: What You Should Know
by Zacks Equity Research
LabCorp (LH) closed the most recent trading day at $264.88, moving +0.24% from the previous trading session.
LabCorp (LH) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
LabCorp (LH) closed the most recent trading day at $263.66, moving -1.99% from the previous trading session.